{"id":"W4284987950","doi":"10.1016/s1470-2045(22)00335-7","title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Clinical endpoint; Progressive disease; CD20; Follicular phase; Lymphoma; Oncology; Rituximab; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001037941,0.0001752809,0.0008325018,0.0001819736,0.0001343032,0.000007697706,0.0002469668,0.00006305294,0.0009686145],"category_scores_gemma":[0.0001644679,0.0001084175,0.00004718837,0.000591484,0.0002261524,0.00003652408,0.000237189,0.0004016471,0.000003470654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006856475,"about_ca_system_score_gemma":0.0002938883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001826802,"about_ca_topic_score_gemma":0.0001675059,"domain_scores_codex":[0.997354,0.0009068666,0.000416166,0.0003692432,0.00053079,0.0004228957],"domain_scores_gemma":[0.9982909,0.000692657,0.0001976274,0.0006369515,0.00009158453,0.00009027102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4685131,0.09002679,0.25896,0.0001361704,0.0008119175,0.001873121,0.01520236,0.0001249807,0.01637679,0.00004844667,0.0005647847,0.1473615],"study_design_scores_gemma":[0.3183252,0.0727651,0.5026208,0.00006065432,0.0002318841,0.0001035211,0.00402817,0.0003231793,0.0001845417,0.00001095796,0.101091,0.0002550238],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955609,0.0002536065,0.000004515393,0.0005407225,0.0001050457,0.002364668,0.00002981966,0.0000307758,0.001109952],"genre_scores_gemma":[0.9986775,0.0001100402,0.0001148957,0.0002038768,0.00008862918,0.00006504554,0.00005946916,0.00003643501,0.0006440926],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2436609,"threshold_uncertainty_score":0.9999446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04388713937975811,"score_gpt":0.3604510344685047,"score_spread":0.3165638950887466,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}